Seeking Alpha

MiMedx to top $400M in revenue by 2018: Lake Street

  • Lake Street initiates MiMedx (MDXG.PK) at Buy.
  • The company is set to triple revenue for its wound care product EpiFix and double sales of AminoFix, its soft-tissue repair offering, analysts say.
  • The company also "has a foundation of strong intellectual property (100+ patents) and is led by an experienced management team with a history of successfully building and selling medical companies."
  • Ultimately, Lake Street thinks the company can top $400M in revenue and generate $100M in EBITDA "in the next four to five years."
  • Price target is $7.50.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: